Migraine, memory loss, and "multiple sclerosis". Neurological features of the antiphospholipid (Hughes') syndrome

被引:103
|
作者
Hughes, GRV [1 ]
机构
[1] St Thomas Hosp, Lupus Unit, London SE1 7EH, England
关键词
D O I
10.1136/pmj.79.928.81
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The antiphospholipid syndrome (APS, Hughes' syndrome), first described in 1983, is a prothrombotic disease in which neurological events feature prominently. Strokes, transient ischaemic attacks, and headaches (including migraine) are important complications. However, it is clear that other neurological symptoms, including diplopia, memory loss, ataxia, and "multiple sclerosis-like" features are common. A notable feature of Hughes' syndrome is the clinical response to anticoagulants; features such as headache and memory loss often improving dramatically with appropriate warfarin dosage. APS may well become recognised as an important (and potentially treatable) cause of neurological disease.
引用
收藏
页码:81 / 83
页数:3
相关论文
共 50 条
  • [31] Evoked potential studies in the antiphospholipid syndrome: differential diagnosis from multiple sclerosis
    Paran, D
    Chapman, J
    Korczyn, AD
    Elkayam, O
    Hilkevich, O
    Groozman, GB
    Levartovsky, D
    Litinsky, I
    Caspi, D
    Segev, Y
    Drory, VE
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (04) : 525 - 528
  • [32] Is inflammation atherogenic in neurological diseases? A case-control study with migraine and multiple sclerosis patients
    Gonzalez Quintanilla, V.
    Toriello, M.
    Gutierrez Gonzalez, S.
    Fernandez Fernandez, J.
    Hadri, O.
    Viadero, R.
    Lopez Garcia, S.
    Palacio, E. J.
    Oterino, A.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 371 - 371
  • [33] Is inflammation atherogenic in neurological diseases? A case-control study with migraine and multiple sclerosis patients
    Quintanilla, V. G.
    Toriello, M.
    Castillo, J.
    Fernandez, J.
    Martinez-Nieto, R.
    Montes, S.
    Pons, E.
    Gutierrez, S.
    Palacio, E.
    Oterino, A.
    JOURNAL OF HEADACHE AND PAIN, 2014, 15
  • [34] Recurrent strokes and memory loss in a patient with triple-positive antiphospholipid antibody syndrome
    Osuorji, Chinenye
    Bilal, Jawad
    Osuorji, Ikenna
    BMJ CASE REPORTS, 2022, 15 (03)
  • [35] Can neurologic antiphospholipid antibody syndrome (APS) be distinguished from multiple sclerosis (MS)?
    Tenedios, F
    Lockshin, MD
    ARTHRITIS AND RHEUMATISM, 2005, 52 (12): : 4079 - 4079
  • [36] Antiphospholipid IgM and IgG Distinguishes the Clinical Phenotypes of Multiple Sclerosis and Clinically Isolated Syndrome
    Frese, K.
    Patel, P.
    Becquart, P.
    Carruthers, R.
    Traboulsee, A.
    Sayao, A.
    Schabas, A.
    Moore, W.
    Vavasour, I. M.
    Laule, C.
    Quandt, J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 178 - 179
  • [37] Clinical features of Sjogren's syndrome in patients with multiple sclerosis
    Annunziata, P.
    De Santi, L.
    Di Rezze, S.
    Millefiorini, E.
    Capello, E.
    Mancardi, G.
    De Riz, M.
    Scarpini, E.
    Vecchio, R.
    Patti, F.
    ACTA NEUROLOGICA SCANDINAVICA, 2011, 124 (02): : 109 - 114
  • [38] MEMORY PERFORMANCE IN CHRONIC FATIGUE SYNDROME AND MULTIPLE-SCLEROSIS
    JOHNSON, SK
    NATELSON, BH
    BELDOWICZ, D
    DELUCA, J
    ARCHIVES OF CLINICAL NEUROPSYCHOLOGY, 1994, 9 (02) : 144 - 145
  • [39] Bone loss and fractures in multiple sclerosis: focus on epidemiologic and physiopathological features
    Dionyssiotis, Yannis
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2011, 4 : 505 - 509
  • [40] ORAL PHYSOSTIGMINE IN THE TREATMENT OF MEMORY LOSS IN MULTIPLE-SCLEROSIS (MS)
    UNVERZAGT, FW
    RAO, SM
    ANTUONO, PG
    JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY, 1991, 13 (01) : 74 - 74